Steinar Johan Engelsen

Teknoinvest AS (Teknoinvest) is a venture capital firm headquartered in Oslo, Norway, with offices in New York, and Stockholm, Sweden. The firm was founded in 1984 by Bjørn Bjorå.

Angiogenix, Inc. develops therapeutic solutions for chronic vascular disease. Its products help the body produce new blood vessels to increase blood flow. The company's product ACCLAIM treats chronic ischemia (lack of oxygen in the heart muscle). Angx1039 is being developed to treat peripheral vascular disease (a narrowing of the vessels carrying blood to the legs, arms and internal organs) and Angx3227 targets sickle cell disease (an inherited disorder that affects the shape of red blood cells). Its fourth product, Vasotrophin increases blood vessel density. The company is headquartered at Burlingame, CA

INSMED Pharmaceuticals, Inc. develops products for the diagnosis and treatment of conditions associated with insulin resistance. The company is headquartered in Richmond, VA.

Nycomed Pharma Holding A/S operates as a holding company with an interest in manufacturing generic drugs. It is active in therapeutic areas, such as cardiology, gastroenterology, osteoporosis, respiratory, and pain and tissue management. The company develops, manufactures, and markets products through Nycomed Pharma A/S. Nycomed Pharma Holding is headquartered in Roskilde, Denmark.

Affitech AS discovers and develops human therapeutic antibodies. It focuses on molecule and cell based antibody discovery. The company was founded by Martin Welschof, Ole Jorgen Marvik, and Michael Braunagel in 1997 and is headquartered in Oslo, Norway.

Engelsen Invest AS operates as a venture capital firm. It engages in portfolio investment services. The firm provides investment services such as investment trusts. The company was founded on June 15, 2001 and is headquartered in Stabekk, Norway.